Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo

Telomir Pharmaceuticals, Inc.

New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.
Telomir-1 outperformed rapamycin and chemotherapy in reactivating the master tumor suppressor CDKN2A.
Findings build on prior STAT1 data, supporting Telomir-1 as a broad-spectrum DNA methylation reset therapy.
Company advancing pre-IND program with CMC and IND-enabling studies toward first IND submission.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.